In the latest trading session, 0.52 million Fate Therapeutics Inc (NASDAQ:FATE) shares changed hands as the company’s beta touched 2.25. With the company’s most recent per share price at $0.74 changed hands at -$0.01 or -1.71% at last look, the market valuation stands at $84.80M. FATE’s current price is a discount, trading about -864.86% off its 52-week high of $7.14. The share price had its 52-week low at $0.66, which suggests the last value was 10.81% up since then. When we look at Fate Therapeutics Inc’s average trading volume, we note the 10-day average is 2.08 million shares, with the 3-month average coming to 2.31 million.
Analysts gave the Fate Therapeutics Inc (FATE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.46. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended FATE as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Fate Therapeutics Inc’s EPS for the current quarter is expected to be -0.38.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Instantly FATE was in red as seen in intraday trades today. With action -6.34%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -55.15%, with the 5-day performance at -6.34% in the red. However, in the 30-day time frame, Fate Therapeutics Inc (NASDAQ:FATE) is -26.73% down. Looking at the short shares, we see there were 14.57 million shares sold at short interest cover period of 4.27 days.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need an upside of 81.5% from its recent market value. According to analyst projections, FATE’s forecast low is 3 with 5 as the target high. To hit the forecast high, the stock’s price needs a -575.68% plunge from its current level, while the stock would need to soar -305.41% for it to hit the projected low.
Fate Therapeutics Inc (FATE) estimates and forecasts
Year-over-year growth is forecast to reach -66.32% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 1.18M. 9 analysts are of the opinion that Fate Therapeutics Inc’s revenue for the current quarter will be 1.18M. The company’s revenue for the corresponding quarters a year ago was 1.93M and 6.77M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -38.47%. The estimates for the next quarter sales put growth at -82.56%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.63%. The 2025 estimates are for Fate Therapeutics Inc earnings to increase by 6.53%, but the outlook for the next 5-year period is at 8.34% per year.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.24% of Fate Therapeutics Inc shares while 89.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 91.86%. There are 89.81% institutions holding the Fate Therapeutics Inc stock share, with REDMILE GROUP, LLC the top institutional holder. As of 2024-06-30, the company held 11.2107% of the shares, roughly 13.17 million FATE shares worth $43.19 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.4544% or 10.57 million shares worth $34.67 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 3.05 shares estimated at $2.58 million under it, the former controlled 2.66% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.25% of the shares, roughly 2.57 shares worth around $2.18 million.
